[EPIC-AML] Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation
Ente: EC
Scadenza: 2029-08-31
Importo max: 193.643 EUR
Paese: EU
Descrizione
EP300 and CBP are crucial lysine acetyltransferases regulating enhancer-dependent transcription via scaffolding and enzymatic activities. They are appealing targets in cancer due to their role in cell cycle control and their druggability. In particular, small molecules targeting the EP300/CBP bromodomains have shown promising activity in haematological malignancies. CCS1477, the first clinical-grade EP300/CBP bromodomain inhibitor, has demonstrated encouraging preclinical and early-phase clinical activity in Acute Myeloid Leukaemia (AML) and Multiple Myeloma (MM). It induces cell cycle arrest and differentiation by displacing EP300/CBP from enhancer sites occupied by key transcription factors (TFs). However, only a subset of patients responds effectively to CCS1477 monotherapy. This project aims to identify novel synergistic drug combinations involving EP300/CBP bromodomain inhibitors to enhance their therapeutic efficacy in AML. Beyond the bromodomain, it will define the regions of EP300/CBP essential for AML growth and uncover functional, potentially targetable interactors bound at these sites to guide future drug development. During the MSCA fellowship, the researcher will spend 24 months at the University of Parma (UNIPR), under the supervision of Prof. Giovanni Roti, an expert in functional genomics and high-throughput drug screening in blood cancers. These approaches are critical for project success and represent key transferable skills for the researcher’s career. The fellow will undertake professional development and scientific training courses, attend seminars and international conferences, prepare two manuscripts for submission to high-impact journals, and organise public engagement activities to maximise the project’s impact within both the scientific and lay communities. This fellowship will significantly advance Dr. Nicosia’s career and support his long-term goal of leading an independent research group in translational epigenetics in blood cancer.
Settori: Horizon Europe Topics
Vai al bando originale
Registrati gratis su Bandolo per trovare bandi compatibili con la tua azienda.